New Findings on EBGLYSS: Three-Year Sustained Response for Patients with Atopic Dermatitis
According to a recent press release from Eli Lilly and Company, new data from the ADjoin long-term extension study reveals that EBGLYSS, an interleukin-13 (IL-13) inhibitor, achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at the three-year mark. These findings will be presented at the American Academy of Dermatology (AAD) Annual Meeting, held March 7-11 in Orlando.
Efficacy of EBGLYSS in Atopic Dermatitis
EBGLYSS selectively blocks IL-13 signaling, making it an effective treatment for atopic dermatitis. IL-13 is a primary cytokine in this condition, causing the type-2 inflammatory cycle in the skin and contributing to skin barrier dysfunction, itch, skin thickening, and infection. Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved the highest bar of complete skin clearance (EASI 100 or IGA 0), and 87% achieved almost-clear skin (EASI 90) at three years with single monthly maintenance injections.
Improvements Beyond Skin Clearance
Additional studies have shown that EBGLYSS significantly improved itch, skin pain, and sleep loss due to itch for a range of patients with atopic dermatitis. These findings are crucial as they demonstrate that EBGLYSS offers more than just skin clearance, addressing some of the most bothersome symptoms of the condition.
Approval and Availability of EBGLYSS
EBGLYSS was approved in the U.S. in September 2024 as a first-line monotherapy biologic treatment option following topical prescription therapies. These new findings further solidify its place in the atopic dermatitis treatment landscape.
Personal Impact
If you or someone you know is living with atopic dermatitis, these new findings may offer hope for long-lasting relief from symptoms. Speak with your healthcare provider about EBGLYSS and whether it could be a suitable treatment option for you. Remember, each person’s experience with atopic dermatitis is unique, and what works best may vary from person to person.
Global Impact
These findings could have a significant impact on the global atopic dermatitis community, as they demonstrate the potential for long-term, effective treatment for this debilitating condition. As more people gain access to EBGLYSS and other innovative treatments, the collective quality of life for those living with atopic dermatitis may improve, leading to better overall health and well-being.
Conclusion
The latest data from the ADjoin long-term extension study highlights the deep and sustained response of EBGLYSS in treating moderate-to-severe atopic dermatitis. With its ability to improve symptoms beyond skin clearance, EBGLYSS represents an important advancement in the field of atopic dermatitis treatment. If you or someone you know is living with this condition, discuss EBGLYSS and its potential benefits with your healthcare provider. Together, we can work towards finding the most effective treatment for managing atopic dermatitis and improving the lives of those affected.
- EBGLYSS is a selective IL-13 inhibitor that blocks IL-13 signaling
- Among Week 16 responders, 50% achieved complete skin clearance and 87% almost-clear skin at three years
- EBGLYSS significantly improved itch, skin pain, and sleep loss due to itch
- Approved in the U.S. as a first-line monotherapy biologic treatment option following topical prescription therapies
- New findings offer hope for long-lasting relief from atopic dermatitis symptoms
